Levonorgestrel-releasing intrauterine device (Mirena®) and breast cancer: what do we learn from literature for clinical practice?;Dispositif intra-utérin au lévonorgestrel (Mirena®) et cancer du sein : que nous apporte la littérature pour la pratique quotidienne ?

Gynecologie Obstetrique et Fertilite

Volumn 34, Issue 11, 2006, Pages 1015-1023

  Boutet, G ^a  

^a Cabinet de Gynecologie   (France)

Author keywords

Breast cancer; Levonorgestrel releasing intrauterine device

Indexed keywords

LEVONORGESTREL; TAMOXIFEN; TAMOXIFEN CITRATE; VALERIC ACID;

ANTECEDENT VARIABLE; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FOLLOW UP; FRANCE; GYNECOLOGY; HUMAN; INFORMED CONSENT; INTRAUTERINE CONTRACEPTIVE DEVICE; LITERATURE; MENOPAUSE; OVARY FUNCTION; RISK FACTOR; SIDE EFFECT;

EID: 33751510645     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2006.09.015     Document Type: Article

References (59)

1. Estève J. Qui ? Combien ? Tentative de description démographique de la population concernée. Lett. Sénol 29 suppl 1 (2005) 4-6
2. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 65 (2000) 699-702
3. Backman T. Benefit-risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf. 27 (2004) 1185-1204
4. Chi I.C. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDS. Contraception 44 (1991) 573-588
5. Faculty of family planning and repoductive health care clinical effectiveness unit. FFPRHC Guidance (April 2004). The levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J. Fam. Plann. Reprod. Health Care 30 (2004) 99-108
6. French R.S., Cowan F.M., Mansour D., Higgins J.P., Robinson A., Procter T., et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG 107 (2000) 1218-1225
7. French R., Van Vliet H., Cowan F., Mansour D., Morris S., Hughes D., et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst. Rev. 3 (2004) (CD001776)
8. Hurskainen R., Teperi J., Rissanen P., Aalto A.M., Grenman S., Kivelä A., et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomised trial 5-year follow-up. JAMA 291 (2004) 1456-1463
9. Lethabi A.E., Cooke I., and Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst. Rev. 4 (2005) (CD002126)
10. Myers E.R. Levonorgestrel-releasing intrauterine system for menorrhagia cost less than hysterectomy over 5 years. Evidence-based Obstet. Gynecol. 7 (2005) 23-24
11. Pakarinen P., Toivonen J., and Luukkainen T. Therapeutic use of the LNG IUS, and counselling. Semin. Reprod. Med. 19 (2001) 365-372
12. Sturridge F., and Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf. 15 (1996) 430-440
13. Yaszbek C., Omnès S., Vacher-Lavenu M.C., and Madelenat P. Efficacité et tolérance du système intra-utérin au lévonorgestrel dans la prise en charge des ménorragies fonctionnelles : étude française multicentrique. Gynecol. Obstet. Fertil. 34 (2006) 906-913
14. Raudaskoski T., Tapanainen J., Tomas E., Luotola H., Pekonen F., Ronni-Sivula H., et al. Intrauterine 10 and 20 μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br. J. Obstet. Gynaecol. 109 (2002) 136-144
15. Suhonen S.P., Holmström T., Allonen H.O., and Lähteenmäki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil. Steril. 63 (1995) 336-342
16. Wildemeersch D., Janssens D., and Weyers S. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?. Maturitas 51 (2005) 207-214
17. Luukkainen T., and Nilsson C.G. Sustained intrauterine release of d-norgestrel. Contraception 18 (1978) 451-458
18. Nilsson C.G., Lähteenmäki P., and Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 21 (1980) 225-233
19. Nilsson C.G., Lahteenmaki P.L.A., Luukkainen T., and Robertson D.N. Sustained intrauterine release of levonorgestrel over five years. Fertil. Steril. 45 (1986) 805-807
20. Luukkainen T., Lähteenmäki P., and Toivonen J. Levonorgestrel-releasing intrauterine device. Ann. Med. 22 (1990) 85-90
21. Bilian X., Liying Z., Xuling Z., Mengchun J., Luukkainen T., and Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 41 (1990) 353-362
22. Lockhat F.B., Emembolu J.E., and Konje J.C. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil. Steril. 83 (2005) 398-404
23. Bilian X., Tao Z., Shangchun W., Hongzhu S., and Na X. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception 51 (1995) 359-365
24. Weiner E., Victor A., and Johansson E.D.B. Plasma levels of d-norgestrel after oral administration. Contraception 14 (1976) 563-570
25. Nilsson S., Nygren K.G., and Johansson E.D.B. d-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women. Am. J. Obstet. Gynecol. 129 (1977) 178-184
26. es Journées de la Société française de sénologie et de pathologie mammaire (2004), DaTeBe, Nancy 396-402
27. Backman T., Rauramo I., Jaakkola K., Inki P., Vaahtera K., Launonen A., et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet. Gynecol. 106 (2005) 813-817
28. Trétarre B. Sein. In : Remontet L ed. Évolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. Paris : Institut de veille sanitaire; 2003. p. 99-105. Référence consultable sous format électronique : URL : http://www.invs.sante.fr.
29. Espié M. Tamoxifène, cancer de l'endomètre et dispositif intra-utérin au levonorgestrel. Gynecol. Obstet. Fertil. 31 (2003) 867-871
30. Jones R.L., and Critchley H.O.D. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum. Reprod. 15 suppl 3 (2000) 162-172
31. Rutanen E.M. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Hum. Reprod. 15 suppl 3 (2000) 173-181
32. Bergeron C. Effets sur l'endomètre des oestrogènes et des anti-estrogènes. Gynecol. Obstet. Fertil. 30 (2002) 933-937
33. Elkas J., Armstrong A., Pohl J., Cuttitta F., Martinez A., and Gray K. Modulation of endometrial steroid receptors and growth regulatory genes by tamoxifen. Obstet. Gynecol. 95 (2000) 697-703
34. Cohen I., Bernheim J., Azaria R., Tepper R., Sharony R., and Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol. Oncol. 75 (1999) 136-141
35. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol. Oncol. 94 (2004) 256-266
36. Dellapasqua S., Colleoni M., Gelber R.D., and Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J. Clin. Oncol. 23 (2005) 1736-1750
37. Hoogendoorn W.E. Endometrial cancer risk remained elevated years after stopping tamoxifen treatment for breast cancer. Evidence-based Obstet. Gynecol. 7 (2005) 211-212
38. Swerdlow A.J., Jones M.E., and British Tamoxifen Second Cancer Study Group. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl. Cancer Inst. 97 (2005) 375-384
39. Elkas J., Gray K., Howard L., Petit N., Pohl J., and Armstrong A. The effects of tamoxifen on endometrial insulin-like growth factor-1 expression. Obstet. Gynecol. 91 (1998) 45-50
40. Gardner F.J.E., Konje J.C., Abrams K.R., Brown L.J.R., Khanna S., Al-Azzawi F., et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 356 (2000) 1711-1717
41. Varma R., Sinha D., and Gupta J.K. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) - A systematic enquiry and overview. Eur. J. Obstet. Gynecol. Reprod. Biol. 125 (2006) 9-28
42. Cohen I. Levonorgestrel-releasing intrauterine devices. Lancet 357 (2001) 801
43. Gerber B., Reimer T., Krause A., Friese K., and Müller H. Levonorgestrel-releasing intrauterine devices. Lancet 357 (2001) 801
44. Neven P. Local levonorgestrel to prevent tamoxifen-related endometrial lesions. Lancet 356 (2000) 1698-1699
45. Abu J., Brown L., and Ireland D. Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (Mirena) in a 36-year-old woman. Int. J. Gynecol. Cancer 16 (2006) 1445-1447
46. Jones K., Georgiou M., Hyatt D., Spencer T., and Thomas I. Endometrial adenocarcinoma following the insertion of a Mirena IUCD. Gynecol. Oncol. 87 (2002) 216-218
47. Amant F., Moerman P., Neven P., Timmerman D., Limbergen E.V., and Vergote I. Endometrial cancer. Lancet 366 (2005) 491-505
48. Neven P., De Muylder X., Van Belle Y., Van Hoff I., and Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351 (1998) 36
49. es Journées de la Société Française de Sénologie et de Pathologie Mammaire (2004), DaTeBe, Nancy 424-434
50. Browne-Martin K., and Longcope C. Regulation of sex hormone-binding globulin secretion in human hepatoma G2 cells. Steroids 66 (2001) 605-607
51. Bertolissi A., Cartei G., Turrin D., Cioschi B., and Rizzi V. Behaviour of vaginal epithelial maturation and sex hormone binding globulin in post-menopausal breast cancer patients during the first year of tamoxifen therapy. Cytopathology 9 (1998) 263-270
52. Dhar K.K., NeedhiRajan T., Koslowski M., and Woolas R.P. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol. Oncol. 97 (2005) 924-927
53. Tjalma W.A., Trinh X.B., and van Dam P.A. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet. Gynecol. 107 (2006) 207
54. Trinh X.B., van Dam P.A., and Tjalma W.A.A.A. Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: do they have any significance?. Maturitas 55 (2006) 94-95
55. Plu-Bureau G, Touraine P, Kuttenn F. Sein et hormones. Encycl Med Chir, Gynécologie 2002 ; 810-A-10 : 1-19.
56. Backman T., Rauramo I., Jaakkola K., Inki P., Vaahtera K., Launonen A., et al. Reply on Tjalma WA, Trinh XB, van Dam PA. Use of the Levonorgestrel-releasing intrauterine system and breast cancer. Obstet. Gynecol. 107 (2006) 208
57. OMS. Critères de recevabilité pour l'adoption et l'utilisation continue des méthodes contraceptives. Genève : OMS; 2005. Référence consultable sous format électronique : URL : http://who.int.
58. Afssaps-Anaes-Inpes. Recommandations pour la pratique clinique. Stratégies de choix des méthodes contraceptives chez la femme. Afssaps, Anaes, Inpes : Paris; 2004. Référence consultable sous format électronique : URL : http://afssaps.sante.fr.
59. SOGC et GOC. Directives cliniques communes. Contraception hormonale ne contenant qu'un progestatif et contraception non hormonale chez les survivantes du cancer du sein : une analyse et une opinion de comité communes de la Société des obstétriciens et gynécologues du Canada et de la Société des gynécologues oncologues du Canada. J. Obstet. Gynaecol. Can. 28 (2006) 627-639